Evidence map›Paper›PMID 37448673›Full record

ArticleIranian journal of microbiology2023

Investigating the effect of

Parastoo Hosseini, Abbas Rahimi Foroushani, Arezoo Marjani, Mahnaz Tavakoli, Abdollah Amiri, Amin Hosseini, Atefeh Bahavar, Sayed-Hamidreza Mozhgani, Mehdi Norouzi

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Iranian journal of microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Parastoo HosseiniDepartment of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Abbas Rahimi ForoushaniDepartment of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Arezoo MarjaniDepartment of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Mahnaz TavakoliDepartment of Medical Microbiology, School of Medical Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abdollah AmiriStudent Research Committee, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.
Amin HosseiniDepartment of Computer, Faculty of Engineering, Raja University, Qazvin, Iran.
Atefeh BahavarDepartment of Microbiology, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran.
Sayed-Hamidreza MozhganiDepartment of Microbiology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.
Mehdi NorouziDepartment of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Tehran University of Medical Sciences · IRJahrom University of Medical Sciences · IRGolestan University · IRShahid Beheshti University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objectives: HTLV-1 is responsible for two important diseases, HAM/TSP and ATLL. Approximately 10 to 20 million people are infected with HTLV-1 worldwide. Identifying altered genes in different cancers is crucial for finding potential treatment strategies. One of the proteins of the RAS/MAPK signaling pathway is MEK1, which is made from the Materials and Methods: Ten ATLL and 10 healthy control individuals were investigated in this study. We used ELISA test to screen anti-HTLV-I antibodies and PCR for confirmation of infection. Then, we extracted total RNA from fresh whole blood, and cDNA was synthesized. The expression levels of the Results: Conclusion: These results could be a perspective in the prevention, prognosis, and targeted treatment of diseases in which the

Indexed as

Adult T-cell leukemia/lymphomaHTLV-I-associated myelopathyKeywords: Human T-lymphotropic virus type 1MAP kinase/ERK kinaseMitogen-activated protein kinase kinase 1Tropical spastic paraparesis

Identifiers

PMID37448673
PMCPMC10336286
OpenAlexW4381113373

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.